Resverlogix Corp. RVX.TO
Nov 4, 2026, 1:12 PM EST
- YTD
- -20.00%
- 1 year
- -20.00%
- Market cap
- 27.54M
- EPS (ttm)
- -0.04
- Shares out
- 280.65M
- Forward P/E
- -0.25
- YTD return
- -20.00%
- 1-year return
- -20.00%
- Volume
- 64.01K
- Avg volume
- 23.45K
- Open
- 0.08
- Previous close
- 0.075
- Day's range
- 0.07 – 0.08
- 52-week range
- 0.07 – 0.15
3M -0.0200 (-21.05%)
Key statistics
- Enterprise value
- 80.30M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 12.29M
- Total cash
- 43.00K
- Total debt
- 65.25M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 0.0632
- 200-day average
- 0.0623
Next earnings
Consensus EPS estimate 0.00.
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- resverlogix.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on RVX.TO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Captrust Financial Advisors | 0.00% | 4,000 | 219 | Jun 29, 2022 |